Literature DB >> 3220967

A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.

G Chouinard1, L Annable, A Ross-Chouinard, P Mercier.   

Abstract

In a 5-year longitudinal study in a cohort of 169 schizophrenic outpatients treated with neuroleptics, we found a twofold increase (from 22% to 44%) in prevalence of tardive dyskinesia (TD) meeting the Schooler and Kane research diagnostic criteria. If we include cases of TD that were considered definite but did not meet the research criteria, the prevalence increased from 31% to 58%. In the cohort of 131 patients who did not present with the disorder in 1975, we found parkinsonism and increase in parkinsonism to be the best predictors of subsequent development of the disorder. Poor schizophrenic prognosis and long treatment duration also appeared to be risk factors. Another finding was the importance of changes in neuroleptic and antiparkinsonian dosage in both covering and uncovering TD.

Entities:  

Mesh:

Year:  1988        PMID: 3220967

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

Review 1.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

2.  Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Authors:  Stanley N Caroff; Vicki G Davis; Del D Miller; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; E Cabrina Campbell; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

Review 3.  Managing antipsychotic-induced tardive dyskinesia.

Authors:  G Gardos
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 4.  Interrelations between psychiatric symptoms and drug-induced movement disorder.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.

Authors:  Yasunori Oda; Yuko Fujita; Kengo Oishi; Yusuke Nakata; Masayuki Takase; Tomihisa Niitsu; Nobuhisa Kanahara; Yukihiko Shirayama; Kenji Hashimoto; Masaomi Iyo
Journal:  Psychopharmacology (Berl)       Date:  2017-07-25       Impact factor: 4.530

7.  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Authors:  Scott W Woods; Hal Morgenstern; John R Saksa; Barbara C Walsh; Michelle C Sullivan; Roy Money; Keith A Hawkins; Ralitza V Gueorguieva; William M Glazer
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

8.  Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia.

Authors:  Tadesse Misgana; Niguse Yigzaw; Getachew Asfaw
Journal:  Neuropsychiatr Dis Treat       Date:  2020-08-17       Impact factor: 2.570

9.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

10.  The relationship between motor effects in rats following acute and chronic haloperidol treatment.

Authors:  H A Jørgensen; O A Andreassen; K Hole
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.